Nordisk
EU Panel Recommends Wegovy for Preventing Cardiac Events, Following FDA Lead
Wegovy, EU panel, FDA, cardiac events, weight loss, Novo Nordisk
Novo Nordisk’s Wegovy Receives UK Approval to Reduce Cardiovascular Risks in Overweight and Obese Adults
Wegovy, Novo Nordisk, UK approval, cardiovascular risks, weight loss, obesity, GLP-1 receptor agonist, semaglutide
Layoffs Persist, GLP-1s Launch for Weight Loss in China
GLP-1, weight loss, China, Novo Nordisk, Eli Lilly, layoffs, biopharma industry, semaglutide, tirzepatide, obesity, diabetes
Eli Lilly, Novo Nordisk Shares Fall as their weight-Loss drugs face competition
, Eli Lilly, Novo Nordisk, Roche, Obesity drugs, Weight-loss drug market, Stock market, Pharmaceutical competition, GLP-1 therapy, CT-996, Zepbound, Wegovy,
Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns
Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy
FDA Rejects Novo Nordisk’s Once-Weekly Insulin Icodec for Diabetes Treatment
FDA, Novo Nordisk, Icodec, Weekly Insulin, Diabetes Treatment, Type 1 Diabetes, Type 2 Diabetes, Complete Response Letter
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans
Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build
Novo Nordisk Wins Approval in China for GLP-1 Obesity Drug Wegovy
Novo Nordisk, Wegovy, GLP-1, Obesity, China, Weight Loss, Semaglutide, Ozempic
Eli Lilly’s Zepbound Shows Promise in Treating Sleep Apnea, Seeks FDA Approval
Zepbound, Eli Lilly, sleep apnea, FDA approval, Novo Nordisk, Wegovy, weight loss, diabetes, pharmaceuticals